Last reviewed · How we verify
NCT04577742
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.
trial testing 106 Ruthenium plaque brachytherapy in 106 Ruthenium Plaque Brachytherapy in 350 participants. Completed in 30 March 2020.
20 March 2020
Quick facts
| Lead sponsor | Federico II University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 February 2011 |
| Primary completion | 20 March 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- 106 Ruthenium plaque brachytherapy
Conditions studied
- 106 Ruthenium Plaque Brachytherapy — all drugs for 106 Ruthenium Plaque Brachytherapy →
- Uveal Melanoma — all drugs for Uveal Melanoma →
Sponsor
Federico II University
Who can join
Adults 40 to 80, any sex, with 106 Ruthenium Plaque Brachytherapy or Uveal Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds.
Amiri M, Molavi O, Sabetkam S, Jafari S, et al · · 2023 · cited 43× · PMID 37705051 · DOI 10.1186/s12935-023-03058-7 -
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.
Cennamo G, Montorio D, D' Andrea L, Farella A, et al · · 2021 · cited 13× · PMID 35047387 · DOI 10.3389/fonc.2021.754108
Verify or expand the search:
- PubMed search for NCT04577742
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Federico II University trials
Trials by the same sponsor.
- NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
- NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
- NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
- NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
- NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04577742 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federico II University
- Last refreshed: 8 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04577742.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing